Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...

The list price of Wegovy will be cut in half on January 1, 2027, plummeting from around $1,350 to $675 a month. The cost of ...

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of ...

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects ...

Donald Trump touted his “energy dominance” agenda, claiming American oil production is up 600,000 barrels per day and the US ...

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.

Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next ...